［1］ LI B,ZHANG B,WANG X,et al.Expression signature,prognosis value,and immune characteristics of Siglec-15 identified by pan-cancer analysis ［J］.Oncoimmunology,2020,9(1):1807291.
<br/>［2］ ANGATA T,TABUCHI Y,NAKAMURA K,et al.Siglec-15:an immune system Siglec conserved throughout vertebrate evolution ［J］.Glycobiology,2007,17(8):838-846.
<br/>［3］ QUIRINO MWL,PEREIRA MC,DEODATO DE SOUZA MF,et al.Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters ［J］.Eur J Histochem,2021,65(1):3174.
<br/>［4］ NOWICKI TS,HU-LIESKOVAN S,RIBAS A.Mechanisms of resistance to PD-1 and PD-L1 blockade ［J］.Cancer J,2018,24(1):47-53.
<br/>［5］ WANG J,SUN J,LIU LN,et al.Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy ［J］.Nat Med,2019,25(4):656-666.
<br/>［6］ CAO G,XIAO Z,YIN Z.Normalization cancer immunotherapy:blocking Siglec-15［J］.Signal Transduct Target Ther,2019,4(1):10.
<br/>［7］ 毛艳艳,刘丽丽,黄瑶庆.肿瘤免疫治疗新兴靶点 ［J］.生命科学,2021,33(10):1225-1230.
MAO YY,LIU LL,HUANG YQ.Emerging targets in cancer immunotherapy ［J］.Chinese Bulletin of Life Sciences,2021,33 (10):1225-1230.
<br/>［8］ ANGATA T.Siglec-15:a potential regulator of osteoporosis,cancer,and infectious diseases ［J］.J Biomed Sci,2020,27(1):10.
<br/>［9］ SUN J,LU Q,SANMAMED MF,et al.Siglec-15 as an emerging target for next-generation cancer immunotherapy ［J］.Clin Cancer Res,2021,27(3):680-688.
<br/>［10］ ISHIDA-KITAGAWA N,TANAKA K,BAO X,et al.Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12) ［J］.J Biol Chem,2012,287(21):17493-17502.
<br/>［11］ HIRUMA Y,HIRAI T,TSUDA E.Siglec-15,a member of the sialic acid-binding lectin,is a novel regulator for osteoclast differentiation ［J］.Biochem Biophys Res Commun,2011,409(3):424-429.
<br/>［12］ KAMEDA Y,TAKAHATA M,MIKUNI S,et al.Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis ［J］.Bone,2015,71:217-226.
<br/>［13］ JAEGER M,PINELLI M,BORGHI M,et al.A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis ［J］.Sci Transl Med,2019,11(496):eaar3558.
<br/>［14］ DEWI IMW,CUNHA C,JAEGER M,et al.Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis ［J］.Cell Rep Med,2021,2(5):100289.
<br/>［15］ BHATTACHARYYA C,MAJUMDER PP,PANDIT B.An exome wide association study of pulmonary tuberculosis patients and their asymptomatic household contacts ［J］.Infect Genet Evol,2019,71:76-81.
<br/>［16］ HU J,YU A,OTHMANE B,et al.Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer ［J］.Theranostics,2021,11(7):3089-3108.
<br/>［17］ KORN MA,SCHMITT H,ANGERMULLER S,et al.Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis ［J］.J Immunol,2020,205(10):2595-2605.
<br/>［18］ OKAZAKI T,CHIKUMA S,IWAI Y,et al.A rheostat for immune responses:the unique properties of PD-1 and their advantages for clinical application ［J］.Nat Immunol,2013,14(12):1212-1218.
<br/>［19］ LI CW,LIM SO,XIA W,et al.Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity ［J］.Nat Commun,2016,7:12632.
<br/>［20］ WANG YL,WEI MB,ZHAO WW,et al.Glycosylation of Siglec15 promotes immunoescape and tumor growth ［J］.Am J Cancer Res,2021,11(5):2291-2302.
<br/>［21］ LIU Y,LI X,ZHANG C,et al.LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma ［J］.Cancer Sci,2020,111(10):3693-3704.
<br/>［22］ REN Y,LYU J,GUO Y,et al.Long noncoding RNA TUG1 inhibits tumor progression through regulating Siglec-15-related anti-immune activity in hepatocellular carcinoma ［J］.J Immunol Res,2022,2022:9557859.
<br/>［23］ FAN MK,ZHANG GC,CHEN W,et al.Siglec-15 promotes tumor progression in osteosarcoma via DUSP1/MAPK pathway ［J］.Front Oncol,2021,11:710689.
<br/>［24］ MURUGESAN G,CORREIA VG,PALMA AS,et al.Siglec-15 recognition of sialoglycans on tumor cell lines can occur independently of sialyl Tn antigen expression ［J］.Glycobiology,2021,31(1):44-54.
<br/>［25］ 文朝朝,王晰,魏艳,等.新型肿瘤免疫抑制靶点唾液酸结合免疫球蛋白样凝集素-15的生物信息学预测 ［J］.中国生物制品学杂志,2021,34(02):135-140.
WEN CC,WANG X,WEI Y,et al.Bioinformatics prediction of sialic acid binding lg like lectin-15 as a novel tumor immunosuppressive target ［J］.Chinese Journal of Biologicals,2021,34(02):135-140.
<br/>［26］ JULIEN S,VIDEIRA PA,DELANNOY P.Sialyl-tn in cancer:(how) did we miss the target［J］.Biomolecules,2012,2(4):435-466.
<br/>［27］ TAKAMIYA R,OHTSUBO K,TAKAMATSU S,et al.The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway ［J］.Glycobiology,2013,23(2):178-187.
<br/>［28］ LIU W,JI Z,WU B,et al.Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44 ［J］.FEBS Lett,2021,595(17):2290-2302.
<br/>［29］ BRIARD JG,JIANG H,MOREMEN KW,et al.Cell-based glycan arrays for probing glycan-glycan binding protein interactions ［J］.Nat Commun,2018,9(1):880.
<br/>［30］ LI QT,HUANG ZZ,CHEN YB,et al.Integrative analysis of Siglec-15 mRNA in human cancers based on data mining ［J］.J Cancer,2020,11(9):2453-2464.
<br/>［31］ CHU C,YAO K,LU J,et al.Immunophenotypes based on the tumor immune microenvironment allow for unsupervised penile cancer patient stratification ［J］.Cancers (Basel),2020,12(7):1796.
<br/>［32］ 黄珊,王玉琛,刘笑笑,等.Siglec-15是食管鳞状细胞癌的新型独立预后因子 ［J］.山西医科大学学报,2021,52(03):243-248.
HUANG S,WANG YC,LIU XX,et al.Siglec-15 is an independent prognostic factor of esophageal squamous cell carcinoma ［J］.Journal of Shanxi Medical University,2021,52(03):243-248.
<br/>［33］ CAO X,ZHOU Y,MAO F,et al.Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer ［J］.Int Immunopharmacol,2022,106:108561.
<br/>［34］ LI TJ,JIN KZ,LI H,et al.SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer ［J］.Cancer Lett,2022,530:142-155.
<br/>［35］ CHEN X,MO S,ZHANG Y,et al.Analysis of a novel immune checkpoint,Siglec-15,in pancreatic ductal adenocarcinoma ［J］.J Pathol Clin Res,2022,8(3):268-278.
<br/>［36］ 郑珞,陈佩芳.子宫内膜透明细胞癌的Siglec-15及CD8表达与其预后的关系 ［J］.福建医科大学学报,2021,55(02):132-136.
ZHENG L,CHEN PF.Prognostic implication of Siglec-15 and CD8 expressions in endometrial clear cell carcinoma ［J］.Journal of Fujian Medical University,2021,55(02):132-136.
<br/>［37］ FUDABA H,MOMII Y,HIRAKAWA T,et al.Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients ［J］.Sci Rep,2021,11(1):1206.
<br/>［38］ XU JL,GUO Y.A comprehensive analysis of different gene classes in pancreatic cancer:SIGLEC15 may be a promising immunotherapeutic target ［J］.Invest New Drugs,2022,40(1):58-67.
<br/>［39］ 张思汗,许斌.肿瘤免疫治疗药物的开发现状及展望 ［J］.临床与病理杂志,2021,41(10):2447-2460.
ZHANG SH,XU B.Current status and prospect of tumor immunotherapy drugs development ［J］.International Journal of Pathology and Clinical Medicine,2021,41(10):2447-2460.
<br/>［40］ HAO JQ,NONG JY,ZHAO D,et al.The significance of Siglec-15 expression in resectable non-small cell lung cancer ［J］.Neoplasma,2020,67(6):1214-1222.
<br/>［41］ ZHOU C,TANG J,SUN H,et al.PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer ［J］.Oncotarget,2017,8(35):58457-58468.
<br/>［42］ VELCHETI V,SCHALPER KA,CARVAJAL DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer ［J］.Lab Invest,2014,94(1):107-116.
<br/>［43］ MU CY,HUANG JA,CHEN Y,et al.High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation ［J］.Med Oncol,2011,28(3):682-688.